DoD Reconstructive Transplant, Concept Award | W81XWH 22 RTRP CA

Opportunity Information: Apply for W81XWH 22 RTRP CA

The DoD Reconstructive Transplant Research Program (RTRP) Concept Award (FY22) is a Department of Defense funding opportunity designed to help researchers test bold, unconventional ideas in reconstructive transplantation. The central purpose is to support the exploration of a highly innovative new concept or an untested theory that could address a meaningful, unresolved problem in the field, especially one tied to the program's published FY22 Concept Award Focus Areas. This mechanism is deliberately aimed at high-risk, high-reward work that could open up entirely new directions for research rather than extending, optimizing, or logically continuing an existing research line.

A defining feature of this award is its emphasis on true innovation. Proposals are expected to challenge current thinking, introduce a new framework, or look at persistent problems from a fresh angle. The program makes it clear that incremental improvements built directly on existing published results are not a good fit. Even though the award encourages ambitious, potentially disruptive ideas, applications still need to show a solid scientific rationale and a credible path to producing interpretable results. In other words, the work can be risky in outcome, but it cannot be vague or speculative in design; applicants must explain why the idea makes scientific sense and how the study will generate meaningful information.

Relevance to military needs is a core requirement. Projects must align with at least one of the FY22 RTRP Concept Award Focus Areas and must be responsive to real healthcare needs affecting military Service Members and/or Veterans recovering from traumatic injury. The opportunity also recognizes the broader care ecosystem by including relevance to family members, caregivers, and clinicians, and it notes that outcomes may also benefit the general public. The military relevance requirement signals that projects should connect their potential impact to trauma-related reconstructive challenges and the unique realities of military medicine and recovery.

The submission rules reflect an intentional effort to create a level playing field for evaluation. Preliminary data are not allowed, which is consistent with the program's goal of enabling early-stage concepts that may not yet have pilot results. At the same time, applicants still need to demonstrate feasibility in the sense of having an approach that can yield interpretable findings and a clearly argued rationale. In addition, the review process is blinded at both tiers, meaning reviewers will not know the identity of the Principal Investigator, collaborators, or their institutions. Because of this, the application must be carefully prepared to avoid revealing identities in specified sections (such as the Project Narrative, References, list of abbreviations/acronyms/symbols, and the Statement of Work). Applications that accidentally disclose identifying information in those components can be rejected for noncompliance, so applicants are expected to follow the posted guidance closely, including the DoD's list of common blinding mistakes available through eBRAP.

From an eligibility and applicant standpoint, the opportunity is broadly open: eligible applicants are listed as unrestricted, meaning it is generally open to a wide range of entity types unless additional eligibility language narrows it elsewhere in the full announcement. The program explicitly encourages young and early-career investigators to apply, and it states that investigators at or above the postdoctoral fellow level are eligible. This makes the mechanism particularly attractive for researchers who have strong ideas but may not yet have extensive preliminary datasets, while still requiring a rigorous and defensible plan.

Administratively, the opportunity is offered by the Department of Defense through the U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding instrument type includes both cooperative agreements and grants under the science and technology/research and development category (CFDA 12.420). The posted anticipated number of awards was three. The original funding opportunity (W81XWH-22-RTRP-CA) was created on June 14, 2022, with an original closing date of October 19, 2022. The listing shows an award ceiling of 0, which typically indicates that applicants should rely on the full announcement for specific budget limits and that a numeric cap may not be expressed in the simplified listing.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Reconstructive Transplant, Concept Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 14, 2022.
• Applicants must submit their applications by Oct 19, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 RTRP CA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: